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Georgia Vogelsang‘‘The doorstep to the temple of wisdom is knowl-
edge of our own ignorance.’’ Benjamin Franklin.
In this issue, Pidala and colleagues report the ap-
palling state of ignorance and confusion regarding
withdraw of immunosuppression (IS) after allogeneic
hematopoietic stem cell transplantation (allo HCT)
[1]. The authors document marked variation practice
(even within the same transplant group), high esti-
mates of graft-vs-host disease (GVHD) emerging in
the setting of IS taper, and limited confidence of trans-
plant physicians in their therapeutic decisions. The
egress from the temple of stem cell transplant is indeed
a jumbled muddle.
The investigators surveyed the American Society
Blood and Marrow Transplantation members using
a series of clinical vignettes to explore IS management
after allo HCT. Unfortunately, only 21% of physician
members participated, which does add a note of con-
cern over the validity of the results. Even with this ca-
veat, the results are alarming. For example, 25%
indicated that they had no consistent strategy for IS ta-
pering and half said they had no institutional guidelines
for IS tapering. There was marked variation among re-
spondents in the taper schedule both in terms of timing
and drug dose reduction even in the base case of an un-
complicated HLA identical siblingHCT. As the inves-
tigators added complexity to the base case (use of
peripheral blood, unrelated donor graft, relapse post
transplant, and so forth), the variations and uncertainty
increased. Moreover, the respondents estimated that
the IS approach they used was likely to result in recur-
rent acute GVHD (aGVHD) and/or chronic GVHD
(cGVHD) in many patients. A total of 41% reported
that their current strategy for IS management post-
HCT is not adequate, and 26% admitted that they
are either uncomfortable or very uncomfortable with
making decisions in the management of IS post-HCT.Department of Oncology, Johns Hopkins Hospital,
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tainty? There are multiple factors. First, transplanta-
tion has become more diverse. It has gone from 2
basic transplant types (autologous or identical sibling
allogeneic) to almost endless combinations of donor
types and stem cell sources. Results from clinical trials
are often being applied to patients quite different from
the original study group. More concerning, these trials
were designed to look at engraftment and GVHD pro-
phylaxis, not at effective IS tapering. Although some
do report rates of cGVHD, none truly report the bur-
den of GVHD occurring on taper or how many pa-
tients required reinstitution of IS. Thus, transplant
physicians must make their best guess how to adapt
the published regimens to their diverse transplant
types. Second, the patient population has also
changed, expanding to include older patients and pa-
tients with multiple medical illnesses, with marginal
organ reserves. This group of patients has less immu-
nologic plasticity and tolerance induction is likely
more difficult. The growth of cord blood transplants
has introduced a group with the potential for greater
immunologic plasticity. Strikingly, the basic practice
of transplantation in many ways has not changed.
Care of a patient receiving a transplant is usually trans-
ferred to a transplant center for a limited period of
time. This care model has long impeded the study
and care of patients with cGVHD. It certainly contrib-
utes to the lack of research into withdraw of IS. Finally,
the few trials of prolonged IS in an attempt to reduce
the rates of recurrent aGVHD and cGVHD have
produced mixed results with no clear indication that
longer standard IS is better [2]. Likewise, attempts to
prevent cGVHD using immunomodulatory agents
have not proven successful [3]. Indeed, the recent
premature closure of the HOVON 76 trial of Lenali-
domide after reduced-intensity allogeneic transplanta-
tion highlights that the unanticipated (induction of
aGVHD) may occur even with agents that have been
well tolerated in other posttransplant situations
(relapse or progression of multiple myeloma) [4].
Is the situation then a hopeless muddle? Certainly
the Pidala paper [1] shows that transplant physicians
are extremely uncomfortable with the current state
and that there is a wide variation in how patients are
managed. The investigators suggest several possible
approaches to improve our current state of ignorance.
Retrospective studies could examine successful IS1417
1418 Biol Blood Marrow Transplant 17:1417-1418, 2011G. Vogelsangdiscontinuation rates according to tapering schedule.
Prospective observational studies could record the IS
taper and the associated outcomes. They suggest that
this data be used to design prospective randomized
trial comparing best approaches for tapering and dis-
continuation of IS. My own belief is that the often
competing factors listed above that created the muddle
make prospective clinical trials comparing the with-
draw strategies identified as the ‘‘best’’ extremely com-
plicated, time consuming, expensive, and may still
produce equivocal results. The investigators suggest
another path that is more likely to be fruitful. If vali-
dated biomarkers of post-HCT immune tolerance
can be developed, these could be used to generate
a personalized and informed strategy for IS discontin-
uation after alloHCT.Our understanding of the genes
regulating tolerance after transplant has improved sig-
nificantly in solid organ transplantation. As summa-
rized recently in an excellent review in this journal,
the current concept is that tolerant solid organ trans-
plant patients have a state of immune quiescence
with reduced expression of costimulation and immune
response genes, and upregulation of cell cycle control
genes [5]. CD41CD251FoxP31 regulatory T cells and
likely natural killer cells also play important roles in
tolerance. Unfortunately, not much is known about
the corresponding tolerant stem cell transplant pa-
tient, but these same techniques should be able to de-
termine the genetic and cellular profile of tolerant
patients. Should these markers be validated, this would
allow for rationally designed strategies for IS discon-
tinuance. This approach has the multiple benefits. IS
manipulation could be focused on the nontolerant pa-
tients who have the most to gain from success while
sparing the cost and toxicity of IS in that group ofpatients who have already achieved a tolerant state.
These IS manipulations could be directed at the iden-
tified defect. This approach would also avoid the diffi-
culty of having to test IS discontinuance in all the
diverse combinations of transplant types.
To close with another quote from Benjamin
Franklin, ‘‘Being ignorant is not so much a shame, as
being unwilling to learn.’’ This paper is a call to all
that we have much to learn before we are able to opti-
mally manage the final step of the stem cell transplant
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